Browse articles from EyeWorld.org related to diabetes. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ First gene therapy treatment for macular telangiectasia type 2 performed outside of trial
➤ First patient enrolled in Phase 2b study of ocular micro implant for IOP reduction
➤ Fast Track Designation granted to Stargardt gene therapy
➤ FDA Special Protocol Assessment for non-proliferative diabetic retinopathy trial
➤ IDE granted to new glaucoma therapy system
➤ Partnership news
➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported
➤ Phase 2 trial results of gene therapy for diabetic retinopathy
➤ Phase 2 program for tracking glaucoma biomarkers begins
➤ Results from extension study of the first approved treatment for geographic atrophy
➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy
➤ ASCRS news and events
➤ Positive Phase 3 results in trial investigating topical diabetic macular edema treatment
➤ Positive topline results in Phase 3 trials for retinal vein occlusion treatment
➤ IND filed for drug to treat neuropathic corneal pain
➤ Trial for ‘first-in-class anti-VEGF-complement dual targeting drug’ begins dosing patients
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ Positive topline results in Phase 3 clinical trial for allergic conjunctivitis treatment
➤ Phase 1b topline data on investigational dry eye drop
➤ First patients dosed in Phase 1b/2 trial for Wnt agonist antibody
➤ Study: U.S. prevalence of diabetic retinopathy
➤ ASCRS news and events
➤ Results from Phase 2a study evaluating glaucoma drop
➤ Enrollment complete for epi-on crosslinking trial
➤ Phase 2 clinical trial begins for investigational dry eye drop
➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment
➤ Phase 2b trial for wet AMD treatment begins enrollment
➤ ASCRS news and events
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function
➤ AI-enabled screening system receives FDA clearance
➤ Enrollment complete for study evaluating investigational first-line therapy for DME
➤ Updates from two retinitis pigmentosa trials
➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant
➤ BLA for wet AMD, DME, DR treatment accepted with priority review
➤ Topline results from 12-month safety clinical trial for investigational dry eye drug
➤ Companies collaborate for research on sustained release for investigational GA drug
➤ ASCRS news and events
➤ FDA accepts NDA for dry eye treatment
➤ Phase 2 study moves forward for investigational ocular autoimmune therapy
➤ Fast-track designation granted for investigational retinitis pigmentosa treatment
➤ First-in-human feasibility study data from drug-eluting IOL platform
➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy
➤ ASCRS news and events
➤ Small-aperture IOL receives FDA approval
➤ First patient enrolled in new LASIK trial
➤ Safety of sustained-release intravitreal implant confirmed
➤ Dosing complete in Phase 1/2a trial for injectable wet AMD therapy
➤ First patient dosed in light-activated optogenetic monotherapy study
➤ Phase 2 study for investigational new immunomodulator to treat dry eye disease
➤ Partnership created to develop tissue implant therapies
➤ ASCRS news and events
➤ Small-aperture IOL receives approvable letter from the FDA
➤ Topline results from Phase 2 clinical trial for intracanalicular insert for treatment of dry eye disease
➤ First in-human study to target biomarkers in the eye that identify ALS
➤ Study provides better understanding for bilateral effect after unilateral injection of gene therapy
➤ ASCRS news and events
